KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Operating Expenses (2016 - 2025)

Travere Therapeutics' Operating Expenses history spans 15 years, with the latest figure at $162.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 19.62% year-over-year to $162.1 million; the TTM value through Dec 2025 reached $553.6 million, down 0.62%, while the annual FY2025 figure was $553.6 million, 0.62% down from the prior year.
  • Operating Expenses reached $162.1 million in Q4 2025 per TVTX's latest filing, up from $139.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $180.6 million in Q1 2024 to a low of $46.4 million in Q4 2021.
  • Average Operating Expenses over 5 years is $120.2 million, with a median of $123.1 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: tumbled 72.6% in 2021, then soared 149.85% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $46.4 million in 2021, then surged by 149.85% to $116.0 million in 2022, then rose by 20.04% to $139.3 million in 2023, then fell by 2.71% to $135.5 million in 2024, then rose by 19.62% to $162.1 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Operating Expenses are $162.1 million (Q4 2025), $139.9 million (Q3 2025), and $127.1 million (Q2 2025).